Does IVIg administration yield improved immune function in very premature neonates?
Journal Article (Journal Article;Review)
Intravenous immunoglobulin (IVIg) has been evaluated as an adjunctive therapy for neonatal sepsis with modest clinical success despite strong biological plausibility. Multiple factors contribute to this outcome, but perhaps none greater than the limited immune system function in newborns, especially in the very premature neonates. For very premature neonates (<30 weeks gestational age), understanding the effects of IVIg on specific immature immune system functions is particularly relevant given their preponderance to develop sepsis and therefore potentially benefit from IVIg-mediated immunoenhancement. Here, we review the available evidence for enhanced immune function after IVIg administration in very premature neonates and highlight areas for future research.
Full Text
Duke Authors
Cited Authors
- Wynn, JL; Seed, PC; Cotten, CM
Published Date
- October 2010
Published In
Volume / Issue
- 30 / 10
Start / End Page
- 635 - 642
PubMed ID
- 20054335
Electronic International Standard Serial Number (EISSN)
- 1476-5543
Digital Object Identifier (DOI)
- 10.1038/jp.2009.197
Language
- eng
Conference Location
- United States